Trial Profile

A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Mar 2026 According to an Arcutis Biotherapeutics media release, data from the trial will be presented during the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place March 27-31 in Denver.
25 Feb 2026 According to an Arcutis Biotherapeutics media release, Supplemental New Drug Application (sNDA) submission expected in Q2 2026
02 Feb 2026 Positive topline results presented in the Arcutis Biotherapeutics Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com